CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.
News at CenExel
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
Are you a woman living with schizophrenia? We have several clinical trials that might be just right for you. The trials are compensated if you qualify, and transportation is provided. In addition, we provide standard of care treatment while you are in trial.
Inpatient schizophrenia research study. We are currently recruiting for several schizophrenia research clinical trials, inpatient and outpatient.